David Goel’s Zentalis Pharmaceuticals ZNTL Stock Holding History

David Goel’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,959,973	Closed	-$21.1M	–	3
2025 Q3	$21.1M	Hold	13,959,973	–	–	19.75%	3
2025 Q2	$16.2M	Hold	13,959,973	–	–	7.27%	4
2025 Q1	$22.2M	Hold	13,959,973	–	–	6.39%	4
2024 Q4	$42.3M	Hold	13,959,973	–	–	1.97%	5
2024 Q3	$51.4M	Hold	13,959,973	–	–	2.45%	5
2024 Q2	$57.1M	Hold	13,959,973	–	–	0.43%	15
2024 Q1	$220M	Hold	13,959,973	–	–	2.04%	11
2023 Q4	$211M	Hold	13,959,973	–	–	2.18%	11
2023 Q3	$280M	Hold	13,959,973	–	–	3.36%	11
2023 Q2	$394M	Buy	13,959,973 +4,760,000	+52%	+$114M	4.58%	8
2023 Q1	$158M	Hold	9,199,973	–	–	2.15%	10
2022 Q4	$185M	Hold	9,199,973	–	–	3.54%	10
2022 Q3	$199M	Hold	9,199,973	–	–	3.81%	11
2022 Q2	$259M	Buy	9,199,973 +4,850,694	+112%	+$128M	5.86%	8
2022 Q1	$201M	Hold	4,349,279	–	–	2.41%	15
2021 Q4	$366M	Hold	4,349,279	–	–	4.07%	13
2021 Q3	$290M	Buy	4,349,279 +248,540	+6%	+$14.3M	3.3%	13
2021 Q2	$218M	Buy	4,100,739 +279,000	+7%	+$14.9M	2.38%	17
2021 Q1	$166M	Hold	3,821,739	–	–	1.91%	19
2020 Q4	$199M	Hold	3,821,739	–	–	2.15%	18
2020 Q3	$125M	Hold	3,821,739	–	–	1.66%	19
2020 Q2	$184M	Buy	+3,821,739	New	+$147M	2.86%	15

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

David Goel's ZNTL Position: Q4 2025 in Review

David Goel sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2025, closing a stake of 13,959,973 shares — an estimated $21.1M sold.

David Goel first reported a position in ZNTL in Q2 2020 and held it in 22 quarters. The position peaked at $394M in Q2 2023. 86 funds tracked by Wall St. Rank hold ZNTL as of Q4 2025.

David Goel reported no remaining Zentalis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
David Goel sold 13,959,973 Zentalis Pharmaceuticals shares in Q4 2025, an estimated $21.1M.
David Goel first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 22 quarters.
David Goel's Zentalis Pharmaceuticals position peaked at $394M in Q2 2023.
86 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2025.

Based on Matrix Capital Management Company's 13F filing for Q4 2025, filed 13 Feb 2026.